Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

Gastroenterology

Volumn 153, Issue 3, 2017, Pages 753-761

  Middleton, Michael S ^a   Heba, Elhamy R ^a   Hooker, Catherine A ^a   Bashir, Mustafa R ^b   Fowler, Kathryn J ^c   Sandrasegaran, Kumar ^d   Brunt, Elizabeth M ^c   Kleiner, David E ^e   Doo, Edward ^f   Van Natta, Mark L ^g   Lavine, Joel E ^h   Neuschwander Tetri, Brent A ^c   Sanyal, Arun ⁱ   Loomba, Rohit ^a   Sirlin, Claude B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f National Institute of Diabetes and Digestive and Kidney Diseases   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct Comparison; FLINT; NAFLD; Non Invasive

Indexed keywords

OBETICHOLIC ACID; PLACEBO; CHENODEOXYCHOLIC ACID;

ADULT; ADULT DISEASE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGESTIVE TRACT PARAMETERS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGIST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTON DENSITY FAT FRACTION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BIOPSY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; LIVER; OBESITY; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SINGLE BLIND PROCEDURE;

ADIPOSITY; ADULT; AREA UNDER CURVE; BIOPSY; CHENODEOXYCHOLIC ACID; FEMALE; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ROC CURVE; SINGLE-BLIND METHOD;

EID: 85028090816     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.06.005     Document Type: Article

References (31)

1. Machado, M.V., Cortez-Pinto, H., Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterology 20 (2014), 12956–12980.
2. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
3. Wanless, I.R., Lentz, J.S., Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990), 1106–1110.
4. Lazo, M., Clark, J.M., The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liv Dis 28 (2008), 339–350.
5. Machado, M., Marques-Vidal, P., Cortez-Pinto, H., Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45 (2006), 600–606.
6. Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
7. LaBrecque, D.R., Abbas, Z., Anania, F., et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterology 48 (2014), 467–473.
8. Schwimmer, J.B., Middleton, M.S., Deutsch, R., et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 21 (2005), 871–879.
9. Bydder, M., Yokoo, T., Hamilton, G., et al. Relaxation effects in the quantification of fat using gradient echo imaging. Mag Res Imag 26 (2008), 347–359.
10. Yokoo, T., Collins, J.M., Hanna, R.F., et al. Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposed-phase and in-phase imaging. J Magn Res Imag 28 (2008), 246–251.
11. Yokoo, T., Bydder, M., Hamilton, G., et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 251 (2009), 67–76.
12. Yokoo, T., Shiehmorteza, M., Hamilton, G., et al. Estimation of hepatic proton-density fat fraction by magnetic resonance imaging at 3T. Radiology 258 (2011), 749–759.
13. Kang, G.H., Cruite, I., Shiehmorteza, M., et al. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Res Imag 34 (2011), 928–934.
14. Negrete, L.M., Middleton, M.S., Clark, L., et al. Inter-examination precision of magnitude-based magnetic resonance imaging for estimation of segmental hepatic proton density fat fraction (PDFF) in obese subjects. J Magn Res Imag 39 (2013), 1265–1271.
15. Tang, A., Tan, J., Sun, M., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267 (2013), 422–431.
16. Permutt, Z., Le, T.A., Peterson, M.R., et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 36 (2012), 22–29.
17. Le, T.A., Chen, J., Changchien, C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56 (2012), 922–932.
18. Noureddin, M., Lam, J., Peterson, M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58 (2013), 1930–1940.
19. Loomba, R., Sirlin, C.B., Ang, B., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61 (2015), 1239–1250.
20. Tang, A., Desai, A., Hamilton, G., et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 274 (2015), 416–425.
21. Patel, J., Bettencourt, R., Cui, J., et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 9 (2016), 692–701.
22. Argo, C.K., Patrie, J.T., Lackner, C., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 62 (2015), 190–197.
23. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
24. Hamilton, G., Yokoo, T., Bydder, M., et al. In vivo characterization of the liver fat 1H magnetic resonance spectrum. NMR Biomedicine 24 (2011), 784–790.
25. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
26. Lachenbruch, P., Mickey, M., Estimation of error rates in discriminant analysis. Technometrics 10 (1968), 1–11.
27. Bonekamp, S., Tang, A., Mashhood, A., et al. Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imag 39 (2014), 1525–1532.
28. Sasso, M., Beaugrand, M., de Ledinghen, V., et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36 (2010), 1825–1835.
29. Imajo, K., Kessoku, T., Honda, Y., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150 (2016), 626–637.
30. Taouli, B., Serfaty, L., Magnetic resonance imaging/elastography is superior to transient elastography for detection of liver fibrosis and fat in nonalcoholic fatty liver disease (editorial). Gastroenterology 150 (2016), 553–556.
31. Tandra, S., Yeh, M.M., Brunt, E.M., et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 55 (2011), 654–659.